中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (6): 479-488.doi: 10.35541/cjd.20220819
中华医学会皮肤性病学分会免疫学组
收稿日期:2022-11-18
修回日期:2022-12-16
发布日期:2023-06-05
通讯作者:
宋志强；顾恒
E-mail:zhiqiang.song@hotmail.com
Immunology Group, Chinese Society of Dermatology
Received:2022-11-18
Revised:2022-12-16
Published:2023-06-05
Contact:
Song Zhiqiang; Gu Heng
E-mail:zhiqiang.song@hotmail.com
摘要： 【摘要】 慢性诱导性荨麻疹是一组由特定诱因诱发、以风团和/或血管性水肿为主要临床表现的慢性荨麻疹，可伴有瘙痒、刺痛、烧灼、疼痛等不适症状。该病临床表现异质性大，病情迁延反复，对患者生活质量影响较大。为提升我国临床医生对该病的认识，规范疾病诊治行为，中华医学会皮肤性病学分会免疫学组基于近年来国内外关于慢性诱导性荨麻疹诊断和治疗的临床研究进展，通过德尔菲法广泛征询专家意见，并经相关专家多轮讨论，最终形成本共识。
中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023,56(6):479-488. doi:10.35541/cjd.20220819
Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）[J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.doi:10.35541/cjd.20220819
| ［1］ | Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884. |
| ［2］ | 陈奇权, 杨显杰, 顾恒, 等. 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》. 中华皮肤科杂志, 2023,e20220814. doi: 10.35541/cjd.20220814. |
| ［3］ | Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital⁃based multicenter epidemiological study［J］. Allergy, 2014,69（3）:359⁃364. doi: 10.1111/all.12338. |
| ［4］ | Napolitano M, Fabbrocini G, Stingeni L, et al. Prevalence of chronic inducible urticaria in elderly patients［J］. J Clin Med, 2021,10（2）:247. doi: 10.3390/jcm10020247. |
| ［5］ | Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population⁃based study［J］. Chin Med J （Engl）, 2022,135（11）:1369⁃1375. doi: 10.1097/CM9.0000000000002172. |
| ［6］ | Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（9）:3141⁃3161. doi: 10. 1016/j.jaip.2020.05.016. |
| ［7］ | Kulthanan K, Ungprasert P, Tapechum S, et al. Vibratory angioedema subgroups, features, and treatment: results of a systematic review［J］. J Allergy Clin Immunol Pract, 2021,9（2）:971⁃984. doi: 10.1016/j.jaip.2020.09.009. |
| ［8］ | Wang F, Zhao YK, Luo ZY, et al. Aquagenic cutaneous disorders［J］. J Dtsch Dermatol Ges, 2017,15（6）:602⁃608. doi: 10.1111/ddg.13234. |
| ［9］ | Altrichter S, Koch K, Church MK, et al. Atopic predisposition in cholinergic urticaria patients and its implications［J］. J Eur Acad Dermatol Venereol, 2016,30（12）:2060⁃2065. doi: 10.1111/jdv.13765. |
| ［10］ | Raison⁃Peyron N, Philibert C, Bernard N, et al. Cold contact urticaria following vaccination: four cases［J］. Acta Derm Venereol, 2016,96（6）:852⁃853. doi: 10.2340/00015555⁃2358. |
| ［11］ | Raison⁃Peyron N, Litovsky J, Huet P, et al. Cold contact urticaria triggered by a permanent tattoo［J］. J Cosmet Dermatol, 2021,20（8）:2463⁃2465. doi: 10.1111/jocd.13874. |
| ［12］ | Yücel MB, Ertas R, Türk M, et al. Food⁃dependent and food⁃exacerbated symptomatic dermographism: new variants of symptomatic dermographism［J］. J Allergy Clin Immunol, 2022,149（2）:788⁃790. doi: 10.1016/j.jaci.2021.07.030. |
| ［13］ | Liu R, Peng C, Jing D, et al. Identification of gut microbiota signatures in symptomatic dermographism［J］. Exp Dermatol, 2021,30（12）:1794⁃1799. doi: 10.1111/exd.14326. |
| ［14］ | Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ What we know and what we do not know［J］. Allergy, 2021,76（4）:1077⁃1094. doi: 10.1111/all.14674. |
| ［15］ | Lawlor F, Black AK. Delayed pressure urticaria［J］. Immunol Allergy Clin North Am, 2004,24（2）:247⁃258, vi⁃vii. doi: 10. 1016/j.iac.2004.01.006. |
| ［16］ | Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10.1007/s10286⁃017⁃0418⁃6. |
| ［17］ | Lugović Mihić L, Bulat V, Situm M, et al. Allergic hypersensitivity skin reactions following sun exposure［J］. Coll Antropol, 2008,32 Suppl 2:153⁃157. |
| ［18］ | Giménez⁃Arnau AM, Ribas⁃Llauradó C, Mohammad⁃Porras N, et al. IgE and high⁃affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance［J］. Clin Transl Allergy, 2022,12（2）:e12117. doi: 10.1002/clt2.12117. |
| ［19］ | Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032. |
| ［20］ | Lenormand C, Lipsker D. Efficiency of interleukin⁃1 blockade in refractory delayed⁃pressure urticaria［J］. Ann Intern Med, 2012,157（8）:599⁃600. doi: 10.7326/0003⁃4819⁃157⁃8⁃201210160⁃00023. |
| ［21］ | Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd.14543. |
| ［22］ | 刘鑫, 刘念, 陈宏翔. 接触性荨麻疹诊治进展［J］. 中华皮肤科杂志, 2021,54（12）:1114⁃1117. doi: 10.35541/cjd.20200079. |
| ［23］ | Schoepke N, Młynek A, Weller K, et al. Symptomatic dermographism: an inadequately described disease［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:708⁃712. doi: 10.1111/jdv.12661. |
| ［24］ | Mellerowicz EJ, Asady A, Maurer M, et al. Angioedema frequently occurs in cholinergic urticaria［J］. J Allergy Clin Immunol Pract, 2019,7（4）:1355⁃1357.e1. doi: 10.1016/j.jaip. 2018.10.013. |
| ［25］ | Sánchez J, Amaya E, Acevedo A, et al. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors［J］. J Allergy Clin Immunol Pract, 2017,5（2）:464⁃470. doi: 10.1016/j.jaip.2016.09.029. |
| ［26］ | Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090. |
| ［27］ | Schoepke N, Abajian M, Church MK, et al. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism［J］. Clin Exp Dermatol, 2015,40（4）:399⁃403. doi: 10.1111/ced.12547. |
| ［28］ | Magerl M, Abajian M, Krause K, et al. An improved Peltier effect⁃based instrument for critical temperature threshold measurement in cold⁃ and heat⁃induced urticaria［J］. J Eur Acad Dermatol Venereol, 2015,29（10）:2043⁃2045. doi: 10.1111/jdv.12739. |
| ［29］ | Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients［J］. J Dtsch Dermatol Ges, 2020,18（11）:1261⁃1268. doi: 10.1111/ddg.14309. |
| ［30］ | Vergara⁃de⁃la⁃Campa L, Gatica⁃Ortega ME, Pastor⁃Nieto MA, et al. Vibratory urticaria⁃angioedema: further insights into the response patterns to vortex provocation test［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:e699⁃e701. doi: 10.1111/jdv. 16396. |
| ［31］ | Fukunaga A, Oda Y, Imamura S, et al. Cholinergic urticaria: subtype classification and clinical approach［J］. Am J Clin Dermatol, 2022:1⁃14. doi: 10.1007/s40257⁃022⁃00728⁃6. |
| ［32］ | Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372, 1372.e1⁃6. doi: 10. 1016/j.jaci.2013.12.1076. |
| ［33］ | Metz M, Ohanyan T, Church MK, et al. Omalizumab is an effective and rapidly acting therapy in difficult⁃to⁃treat chronic urticaria: a retrospective clinical analysis［J］. J Dermatol Sci, 2014,73（1）:57⁃62. doi: 10.1016/j.jdermsci.2013.08.011. |
| ［34］ | Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire （CU⁃QoL）［J］. Allergy, 2005,60（8）:1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x. |
| ［35］ | Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x. |
| ［36］ | Koch K, Weller K, Werner A, et al. Antihistamine updosing reduces disease activity in patients with difficult⁃to⁃treat cholinergic urticaria［J］. J Allergy Clin Immunol, 2016,138（5）:1483⁃1485.e9. doi: 10.1016/j.jaci.2016.05.026. |
| ［37］ | Ruft J, Asady A, Staubach P, et al. Development and validation of the Cholinergic Urticaria Quality⁃of⁃Life Questionnaire （CholU⁃QoL）［J］. Clin Exp Allergy, 2018,48（4）:433⁃444. doi: 10.1111/cea.13102. |
| ［38］ | Młynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria［J］. Br J Dermatol, 2010,162（1）:198⁃200. doi: 10.1111/j.1365⁃2133.2009.09441.x. |
| ［39］ | Ahsan DM, Altrichter S, Gutsche A, et al. Development of the cold urticaria activity score［J］. Allergy, 2022,77（8）:2509⁃2519. doi: 10.1111/all.15310. |
| ［40］ | Aguilera P. Inducing light tolerance with narrowband UV⁃B therapy in solar urticaria［J］. Actas Dermosifiliogr （Engl Ed）, 2018,109（10）:853. doi: 10.1016/j.ad.2018.06.009. |
| ［41］ | Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse⁃controlled ergometry test for diagnosing and investigating cholinergic urticaria［J］. J Dermatol Sci, 2014,75（2）:88⁃93. doi: 10.1016/j.jdermsci.2014.04.007. |
| ［42］ | Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol, 2018,141（5）:1726⁃1734. doi: 10.1016/j.jaci.2018. 01.031. |
| ［43］ | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
| ［44］ | Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1119⁃1130. doi: 10.1016/j.jaip.2018.03.007. |
| ［45］ | He ZH, Qiu SC, Huang ZW, et al. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: a systematic review and meta⁃analysis［J］. Dermatol Ther, 2022,35（12）:e15928. doi: 10.1111/dth.15928. |
| ［46］ | Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations［J］. BMJ, 2004,328（7454）:1490. doi: 10.1136/bmj.328.7454.1490. |
| ［47］ | Fialek M, Dezoteux F, Le Moing A, et al. Omalizumab in chronic inducible urticaria: a retrospective, real⁃life study［J］. Ann Dermatol Venereol, 2021,148（4）:262⁃265. doi: 10.1016/j.annder. 2021.04.010. |
| ［48］ | Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism⁃results of a randomized placebo⁃controlled trial［J］. J Allergy Clin Immunol, 2017,140（3）:870⁃873.e5. doi: 10.1016/j.jaci.2017.01.042. |
| ［49］ | Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria⁃results of a randomized placebo⁃controlled trial［J］. J Allergy Clin Immunol, 2017,140（3）:864⁃867.e5. doi: 10.1016/j.jaci.2017.01.043. |
| ［50］ | Gastaminza G, Azofra J, Nunez⁃Cordoba JM, et al. Efficacy and safety of omalizumab （Xolair） for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double⁃blind and open⁃label placebo⁃controlled clinical trial［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1599⁃1609.e1. doi: 10.1016/j.jaip.2018.12.025. |
| ［51］ | Aubin F, Avenel⁃Audran M, Jeanmougin M, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study［J］. J Am Acad Dermatol, 2016,74（3）:574⁃575. doi: 10.1016/j.jaad.2015.11.021. |
| ［52］ | Bonnekoh H, Terhorst⁃Molawi D, Buttgereit T, et al. Treatment of severe heat urticaria with omalizumab ⁃ report of a case and review of the literature［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:e489⁃e491. doi: 10.1111/jdv.16407. |
| ［53］ | Rorie A, Gierer S. A case of aquagenic urticaria successfully treated with omalizumab［J］. J Allergy Clin Immunol Pract, 2016,4（3）:547⁃548. doi: 10.1016/j.jaip.2015.12.017. |
| ［54］ | Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio⁃oedema［J］. Clin Exp Dermatol, 2013,38（2）:151⁃153. doi: 10.1111/j.1365⁃2230.2012.04430.x. |
| ［55］ | Can PK, Salman A, Hoşgören⁃Tekin S, et al. Effectiveness of omalizumab in patients with chronic inducible urticaria: real⁃life experience from two UCARE centres［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:e679⁃e682. doi: 10.1111/jdv.17385. |
| ［56］ | Gorczyza M, Schoepke N, Krause K, et al. Patients with chronic cold urticaria may benefit from doxycycline therapy［J］. Br J Dermatol, 2017,176（1）:259⁃261. doi: 10.1111/bjd.14820. |
| ［57］ | Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria［J］. Acta Derm Venereol, 1985,65（5）:449⁃450. |
| ［58］ | Levi A, Enk CD. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity［J］. Photodermatol Photoimmunol Photomed, 2015,31（6）:302⁃306. doi: 10.1111/phpp.12186. |
| ［59］ | Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine⁃resistant symptomatic dermographism: a pilot study［J］. J Am Acad Dermatol, 2008,59（5）:752⁃757. doi: 10.1016/j.jaad.2008. 07.016. |
| ［60］ | Maksimovic L, Frémont G, Jeanmougin M, et al. Solar urticaria successfully treated with intravenous immunoglobulins［J］. Dermatology, 2009,218（3）:252⁃254. doi: 10.1159/000193998. |
| ［61］ | Kulthanan K, Ungprasert P, Tuchinda P, et al. Delayed pressure urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2035⁃2049.e5. doi: 10.1016/j.jaip.2020.03.004. |
| ［62］ | Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria［J］. Allergol Int, 2011,60（3）:277⁃281. doi: 10.2332/allergolint.10⁃OA⁃0269. |
| ［63］ | Rujitharanawong C, Kulthanan K, Tuchinda P, et al. A systematic review of aquagenic urticaria⁃subgroups and treatment options［J］. J Allergy Clin Immunol Pract, 2022,10（8）:2154⁃2162. doi: 10.1016/j.jaip.2022.04.033. |
| ［64］ | Kozel MM, Mekkes JR, Bossuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients［J］. J Am Acad Dermatol, 2001,45（3）:387⁃391. doi: 10.1067/mjd.2001.116217. |
| ［65］ | Bal F, Kahveci M, Soyer O, et al. Chronic inducible urticaria subtypes in children: clinical features and prognosis［J］. Pediatr Allergy Immunol, 2021,32（1）:146⁃152. doi: 10.1111/pai.13324. |
| ［66］ | Dover JS, Black AK, Ward AM, et al. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients［J］. J Am Acad Dermatol, 1988,18（6）:1289⁃1298. doi: 10.1016/s0190⁃9622（88）70137⁃1. |
| ［67］ | Kim JE, Eun YS, Park YM, et al. Clinical characteristics of cholinergic urticaria in Korea［J］. Ann Dermatol, 2014,26（2）:189⁃194. doi: 10.5021/ad.2014.26.2.189. |
| [1] | 焦晴晴 张晓艳 季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 559-562. |
| [2] | 陈奇权 杨显杰 王文稳 梁高澎 宋志强. 胆碱能性荨麻疹临床评估工具的开发及应用进展[J]. 中华皮肤科杂志, 2023, 56(6): 563-566. |
| [3] | 米淑宏 余艳琴 郝金奇 李薇 张杨 贾喜梅 黄毓娴 孙怀玉 石继海. 丘疹脓疱型玫瑰痤疮患者皮肤高频超声联合彩色多普勒血流成像的特征[J]. 中华皮肤科杂志, 2023, 56(6): 540-544. |
| [4] | 梁云生 黎展宏 伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558. |
| [5] | 张立明 肖汀. 慢性自发性荨麻疹的自身免疫发病机制研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 567-570. |
| [6] | 杨娜丽 许秋阳 吴含文 叶雅慧 朱吉玲 刘晶晶 李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524. |
| [7] | 陈奇权 孔敏敏 杨显杰 王欢 李健 张名望 宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503. |
| [8] | 苏畅 隋秀丽 刘瑞玲 曹毅群 姜虹 严彩蓉 王惠平 亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517. |
| [9] | 王鑫 刘丽娟 李邻峰. [开放获取] 我国慢性自发性荨麻疹临床特征：基于多家医院问卷调查的流行病学研究[J]. 中华皮肤科杂志, 2023, 56(6): 525-530. |
| [10] | 李丽俏 彭聪 陈翔 李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511. |
| [11] | 陈奇权 杨显杰 顾恒 徐金华 郝飞 姚煦 宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539. |
| [12] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495. |
| [13] | 《蕈样肉芽肿治疗中国专家共识》编写专家组. [开放获取] 蕈样肉芽肿治疗中国专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 402-409. |
| [14] | 胡清洁 周敏 姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较[J]. 中华皮肤科杂志, 2023, 56(5): 410-414. |
| [15] | 中国医师协会皮肤科医师分会性传播疾病专业委员会. 梅毒血清固定临床管理专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 383-388. |
|
